Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model

Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model

In a mouse model of α-Fas-induced acute liver injury, the orally-administered caspase inhibitor PF-03491390 (formerly named IDN-6556) was retained in the liver for prolonged periods with a low systemic exposure. Reductions in the elevated plasma levels of alanine aminotransferase (ALT) revealed that...

Full description

Bibliographic Details
Main Authors: Yoshinobu Ueno, Takashi Ohmi, Mitsuko Yamamoto, Naoto Kato, Yukiko Moriguchi, Midori Kojima, Rieko Shimozono, Sachiko Suzuki, Tomomi Matsuura, Hiroyuki Eda
Format: Article
Language:English
Published: Elsevier 2007-01-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861319342069

Similar Items

Similar Items